Author

J. Norman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

C. Nixon· 2 shared A. D. Campbell· 1 shared A. J. Chalmers· 1 shared A. Koessinger· 1 shared B. Cadden· 1 shared C. Alexandrou· 1 shared C. Cloix· 1 shared D. Koessinger· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Nixon

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancers

J. A. Waldron, G. Kanellos, R. C. L. Smith, J. R. P. Knight, J. Munro, C. Alexandrou, N. Vlahov, L. Pardo-Fernandez, M. Moore, S. L. Gillen, D. Strathdee, D. Stevenson, F. C. Warrander, K. Gilroy, C. Nixon, , O. J. Sansom

This study shows eIF4A1 is critical for supporting translational demands in Wnt-driven colorectal cancers, while eIF4A2 loss accelerates tumourigenesis, and eFT226 inhibits eIF4A1 function in these models.

bioRxiv · Nov 10, 2023 · PreprintCancer Biology

Increased apoptotic priming of glioblastoma enables therapeutic targeting by BH3-mimetics

A. Koessinger, D. Koessinger, K. Kinch, L. Martinez-Escardo, N. Paul, Y. Elmasry, G. Malviya, C. Cloix, K. Campbell, F. Bock, J. O'Prey, K. Stevenson, C. Nixon, M. Jackson, G. Ichim, , S. Tait

This study shows that glioblastoma (GBM) is highly sensitive to BH3-mimetics due to elevated anti-apoptotic BCL-xL and MCL-1 expression, which can be therapeutically targeted.

bioRxiv · Jun 13, 2021 · PreprintCancer Biology